dc.contributor.author | El-Salhy, Magdy | |
dc.contributor.author | Bråthen Kristoffersen, Anja | |
dc.contributor.author | Valeur, Jørgen | |
dc.contributor.author | Casén, Christina | |
dc.contributor.author | Hatlebakk, Jan Gunnar | |
dc.contributor.author | Gilja, Odd Helge | |
dc.contributor.author | Hausken, Trygve | |
dc.date.accessioned | 2021-09-09T06:14:07Z | |
dc.date.available | 2021-09-09T06:14:07Z | |
dc.date.created | 2021-06-19T13:51:39Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1350-1925 | |
dc.identifier.uri | https://hdl.handle.net/11250/2774781 | |
dc.description.abstract | Background
We recently found fecal microbiota transplantation (FMT) in irritable bowel syndrome (IBS) patients to be an effective and safe treatment after 3 months. The present follow-up study investigated the efficacy and safety of FMT at 1 year after treatment.
Methods
This study included 77 of the 91 IBS patients who had responded to FMT in our previous study. Patients provided a fecal sample and completed five questionnaires to assess their symptoms and quality of life at 1 year after FMT. The dysbiosis index (DI) and fecal bacterial profile were analyzed using a 16S rRNA gene-based DNA probe hybridization. The levels of fecal short-chain fatty acids (SCFAs) were determined by gas chromatography.
Results
There was a persistent response to FMT at 1 year after treatment in 32 (86.5%) and 35 (87.5%) patients who received 30-g and 60-g FMT, respectively. In the 30-g FMT group, 12 (32.4%) and 8 (21.6%) patients showed complete remission at 1 year and 3 months, respectively; the corresponding numbers in the 60-g FMT group were 18 (45%) and 11 (27.5%), respectively. Abdominal symptoms and the quality of life were improved at 1 year compared with after 3 months. These findings were accompanied by comprehensive changes in the fecal bacterial profile and SCFAs.
Conclusions
Most of the IBS patients maintained a response at 1 year after FMT. Moreover, the improvements in symptoms and quality of life increased over time. Changes in DI, fecal bacterial profile and SCFAs were more comprehensive at 1 year than after 3 months. www.clinicaltrials.gov (NCT03822299). | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Wiley | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/deed.no | * |
dc.title | Long-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2021 The Authors | en_US |
dc.source.articlenumber | e14200 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |
dc.identifier.doi | 10.1111/nmo.14200 | |
dc.identifier.cristin | 1916927 | |
dc.source.journal | Neurogastroenterology and Motility | en_US |
dc.identifier.citation | Neurogastroenterology and Motility. 2021, e14200. | en_US |